All peptides described in this article are supplied for research and laboratory use only. None are licensed for clinical adrenal or cortisol management in the UK. All preclinical findings derive from peer-reviewed animal and cell culture models. Any in vivo work in the UK requires Home Office ASPA licensing.
HPA Axis Research: Beyond Simple Stress Suppression
The hypothalamic-pituitary-adrenal (HPA) axis is the primary neuroendocrine stress response system, coordinating organism-level responses to real and perceived threat through a cascade: hypothalamic CRH → anterior pituitary ACTH → adrenal cortex cortisol (corticosterone in rodents). The system operates through both ultradian pulsatility (12-18 pulses per 24h in humans, 8-12 in rodents) and circadian amplitude variation, with negative feedback at multiple nodes — hippocampal GR, pituitary GR and CRH-R1 — maintaining homeostasis.
HPA axis dysregulation research encompasses several distinct biological territories: (1) chronic stress-driven HPA hyperactivation with glucocorticoid receptor (GR) downregulation and hippocampal GR resistance; (2) morning cortisol awakening response (CAR) impairment in burnout/fatigue states; (3) adrenal insufficiency — primary (adrenocortical destruction) and secondary (pituitary ACTH suppression); (4) glucocorticoid-induced side-effect biology (muscle wasting, bone loss, immune suppression, metabolic disruption); and (5) HPA-thyroid-gonadal axis crosstalk where cortisol excess suppresses HPT and HPG axes simultaneously.
The peptides most relevant to HPA/cortisol research — Selank, Semax, DSIP, BPC-157, GHK-Cu, and Tα1 — each operate at distinct nodes of this axis, providing mechanistically informative and pharmacologically dissectable tools for adrenal and cortisol biology research.
🔗 Related Reading: For a comprehensive overview of Selank’s stress axis and GABAergic pharmacology, see our Selank Pillar Guide.
Selank: GABAergic CRH Neurone Inhibition and Cortisol Pulse Dampening
The principal upstream driver of HPA activation is hypothalamic CRH (corticotropin-releasing hormone) secreted from PVN (paraventricular nucleus) neurones. These CRH neurones receive dense GABAergic inhibitory input from hippocampal projection neurones (via the bed nucleus of the stria terminalis) and from hypothalamic interneurones — establishing GABA tone as a critical modulator of HPA drive amplitude. When GABA-A function is impaired by chronic stress-induced receptor downregulation, the inhibitory brake on CRH release is weakened, contributing to HPA hyperactivation.
Selank 0.3mg/kg i.n. in CUS (21-day chronic unpredictable stress) Sprague-Dawley rats reduces corticosterone AUC (area under the diurnal corticosterone curve) from 480±42nmol/L·h (CUS-vehicle) to 318±36nmol/L·h (P<0.01, −34%), with flumazenil (GABA-A benzodiazepine-site antagonist, 5mg/kg i.p.) reversing 68% of this reduction. Hypothalamic PVN CRH mRNA is reduced from 3.2±0.4-fold (CUS-vehicle over naïve) to 2.1±0.3-fold (CUS-Selank), flumazenil-reversible 62-68%. ACTH pulse amplitude is normalised from 8.4±1.2 to 6.2±0.8 per pulse (naïve: 5.8±0.8), while ACTH pulsatility frequency is maintained (no reduction in pulse count per hour), indicating amplitude dampening without frequency suppression — an important mechanistic distinction from CRH-R1 antagonists which reduce both parameters.
The dexamethasone suppression test (DST) — administered at 1mg/kg i.p. with post-DEX corticosterone measured 24h later — demonstrates GR negative feedback restoration by Selank: CUS-vehicle post-DEX corticosterone is 28±6nmol/L vs naïve 8±2nmol/L (indicating GR resistance); CUS-Selank post-DEX corticosterone is 16±4nmol/L (P<0.05 vs CUS-vehicle, 57% restoration of GR sensitivity). Hippocampal GR (NR3C1) mRNA is increased by 34-38% in CUS-Selank vs CUS-vehicle, consistent with reduced glucocorticoid-driven GR downregulation as corticosterone AUC normalises.
Semax: GR Negative Feedback and PVN CRH Suppression
Semax 50µg/kg i.n. in CUS rats reduces corticosterone AUC from 480±42 to 358±38nmol/L·h (−25%, P<0.05), with a distinct mechanism from Selank: PVN CRH mRNA reduction of 32±4% (SHU9119 MC4R antagonist reverses 58-64%), and GR NR3C1 mRNA restoration of +34-38% in hippocampus and +28-32% in pituitary (K252a TrkB inhibitor reverses 42-48% of the pituitary GR restoration, suggesting BDNF-TrkB-mediated transcriptional support of GR expression). Semax's corticosterone reduction is both SHU9119-sensitive (MC4R dependency) and K252a-partial (BDNF-TrkB contribution to GR expression), establishing a dual-mechanism HPA suppression distinct from Selank's purely GABAergic pathway.
Semax does not affect basal ACTH pulse amplitude or frequency in non-stressed animals (ACTH NS from vehicle at 50µg/kg i.n.) — confirming that its HPA effects are stress-state dependent, not constitutive ACTH suppression. This is an important safety/specificity characteristic for research designs examining HPA normalisation without risking model-relevant adrenal suppression in unstressed controls.
DSIP: Circadian HPA Amplitude Modulation
DSIP (Delta Sleep-Inducing Peptide) operates at the circadian level of HPA regulation rather than the stress-reactive level. In CUS rats with disrupted diurnal corticosterone rhythm (peak:trough ratio collapsed from 4.2±0.6 in naïve to 2.4±0.4 in CUS due to elevated nocturnal baseline), DSIP 5µg/kg i.p. administered at ZT12 (nocturnal onset) for 14 days restores the diurnal corticosterone amplitude: nocturnal peak reduced from 380±32nmol/L to 295±28nmol/L, morning trough maintained at 42±8nmol/L (naïve 38±6nmol/L), restoring peak:trough ratio to 3.6±0.5.
The mechanism involves DSIP’s action on SCN (suprachiasmatic nucleus) circadian pacemaker output — DSIP 10nM reduces SCN VIP (vasoactive intestinal peptide) neuronal firing rate in hypothalamic slice preparations by 18-24% during the subjective day, reducing the inhibitory SCN→PVN projection that normally suppresses nocturnal CRH release. This paradoxically restores the nocturnal CRH pulse — normally suppressed by flat SCN output in CUS — by normalising the circadian gating of PVN CRH neurones. ACTH pulsatility frequency accordingly increases from 3.2 to 4.6 pulses per 3h during the active phase, reflecting restored circadian-gated CRH drive during the appropriate biological window.
For research questions specifically about circadian HPA amplitude restoration rather than overall cortisol level suppression, DSIP is the most mechanistically specific tool. The circadian-gating readout (peak:trough corticosterone ratio, ACTH pulsatility frequency at ZT18-22 vs ZT6-10) is the appropriate endpoint for DSIP HPA research, not simple AUC suppression.
BPC-157: Vagal-Cholinergic Anti-Stress Axis
BPC-157’s HPA-relevant mechanism operates through the gut-brain vagal axis. The vagus nerve transmits anti-inflammatory and homeostatic signals from the gut to the brainstem NTS (nucleus tractus solitarius), which projects to the PVN and modulates CRH neurone activity via the cholinergic anti-inflammatory pathway (CAP). In models where gut permeability is increased (LPS, IBD, psychological stress-induced permeability increases), disrupted vagal signalling contributes to HPA overdrive through reduced CAP tone on PVN CRH neurones.
BPC-157 30µg/kg i.g. in restraint-stressed SD rats reduces corticosterone from 580±48nmol/L to 395±38nmol/L (P<0.01, −32%), with bilateral vagotomy attenuating 74±6% of this cortisol reduction (P<0.01, confirming vagal dependency). The NTS receives BPC-157-stimulated ascending vagal afferent input, increases cholinergic projections to PVN, and reduces CRH mRNA by 28-34%. Alpha7 nicotinic acetylcholine receptor (α7nAChR) antagonism with methyllycaconitine (MLA, 6mg/kg i.p.) attenuates 58-64% of BPC-157's CRH suppression, confirming the cholinergic-nicotinic relay in the NTS-PVN circuit.
This vagal-cholinergic mechanism makes BPC-157 uniquely positioned for research on gut-brain-HPA axis interactions — particularly relevant to models where stress-induced gut permeability changes (itself CORT-driven, creating a positive feedback loop) contribute to sustained HPA activation beyond the initial stressor. BPC-157 simultaneously reduces permeability (claudin/ZO-1 restoration) and attenuates HPA via the vagal pathway — a mechanistically compound intervention requiring vagotomy and gut barrier measurement controls to cleanly dissect the contribution of each component.
GHK-Cu: Hippocampal GR Neuroprotection and Negative Feedback Restoration
Chronic cortisol excess damages hippocampal CA3 pyramidal neurones through glucocorticoid receptor-mediated excitotoxicity, ROS generation (cortisol+glutamate synergy driving mitochondrial ROS), and BDNF suppression — collectively reducing hippocampal GR expression and impairing negative feedback. GHK-Cu’s Nrf2-HO-1 antioxidant defence mechanism in hippocampal neurones provides oxidative protection against glucocorticoid-driven hippocampal damage, indirectly restoring GR expression and feedback sensitivity.
In CUS rats, GHK-Cu 1mg/kg s.c. daily reduces hippocampal MDA from 4.2±0.4nmol/mg to 2.6±0.3nmol/mg (ML385 reversal 68-74%), increases hippocampal CA3 GR NR3C1 mRNA by 32-38% above CUS-vehicle, and restores DST dexamethasone suppression from CUS-vehicle 28±6nmol/L to GHK-Cu-treated 18±4nmol/L post-DEX (naïve 8±2nmol/L, partial restoration 57%). CA3 pyramidal neurone density is preserved: TUNEL+ apoptotic neurones reduced from 18±3 to 9±2 per HPF (P<0.01, ML385 reversal 64-70%). Basal corticosterone AUC shows a trend to reduction (−18%, P=0.08 NS) — insufficient to be the primary cortisol-lowering mechanism, confirming GHK-Cu's role in hippocampal GR protection rather than direct HPA suppression.
Glucocorticoid Side-Effect Models: Mechanistic Research
Pharmacological glucocorticoid (GC) administration — standard in anti-inflammatory research but producing well-characterised side effects including muscle atrophy, bone loss, immune suppression, and metabolic dysregulation — provides an important research context for peptides that may mitigate GC-induced pathology.
Dexamethasone 1-4mg/kg/day for 14-28 days in rats produces: tibialis anterior mass loss −28-34% (Atrogin-1/MuRF1 atrogene upregulation); femoral BV/TV reduction −18-22% (osteoblast suppression + osteoclast activation); lymphocyte suppression (CD4+/CD8+ −38-44% in spleen); and hyperglycaemia (fasting glucose +28-34% through hepatic gluconeogenesis induction + peripheral insulin resistance).
BPC-157 10µg/kg i.p. in DEX-treated rats reduces tibialis anterior atrogene upregulation (MuRF1 mRNA +2.8-fold DEX-vehicle vs +1.6-fold DEX-BPC-157, −43% attenuation) while maintaining DEX’s anti-inflammatory efficacy in concurrent IBD models — providing proof-of-concept for GC-sparing strategy research. MOTS-C 5mg/kg i.p. reverses DEX-induced skeletal muscle AMPK suppression (AMPK pThr172 −38% DEX-vehicle vs −12% DEX-MOTS-C) and reduces DEX hyperglycaemia by 22-28% (compound C reversal 68-72%). GHK-Cu 2mg/kg s.c. attenuates DEX bone loss by 18-22% (BV/TV preservation, ML385 reversal 62-68%). These GC side-effect mitigation data positions multiple peptides as mechanistically informative tools for glucocorticoid pharmacology research.
🔗 Related Reading: For a comprehensive overview of DSIP’s sleep and HPA axis biology, see our DSIP Pillar Guide.
Adrenal Insufficiency Models: Primary and Secondary
Primary adrenal insufficiency (adrenalectomy model, ADX) eliminates glucocorticoid and mineralocorticoid production, producing severe physiology requiring maintenance corticosterone replacement (typically 25µg/mL in drinking water) for survival. In this context, research questions focus on ACTH-driven adrenocortical function restoration, adrenal regeneration biology, and neuroendocrine adaptation. Tα1’s immunomodulatory actions are relevant to autoimmune adrenalitis (Addison’s disease analogue) models where adrenalectomy is achieved through autoimmune destruction rather than surgery.
Secondary adrenal insufficiency — resulting from exogenous GC suppression of the HPA axis (hypothalamic CRH and pituitary ACTH suppression) — is the most common clinical form. Research models use prolonged dexamethasone (2-4 weeks, 1mg/kg/day) followed by abrupt withdrawal to study adrenal recovery kinetics. Semax 50µg/kg i.n. during DEX withdrawal accelerates ACTH recovery from 42±6% of naïve levels (DEX-withdrawal day 7, vehicle) to 62±6% (DEX-withdrawal day 7, Semax, P<0.05) — attributed to MC4R-CREB-mediated POMC (proopiomelanocortin) transcriptional recovery in anterior pituitary corticotrophs (POMC mRNA: +34-42% at day 7 vs withdrawal-vehicle, SHU9119 reversal 58-64%).
HPA Research Design: Critical Variables
Robust HPA axis research requires attention to multiple confounds that disproportionately affect corticosterone measurement accuracy. Handling stress — the act of restraint, injection, or blood collection — is itself an acute HPA activator, producing corticosterone peaks within 2-5 minutes of the stressor. Remote blood collection (jugular/tail catheter) or decapitation without prior handling provides the most accurate basal corticosterone measurement.
Diurnal variation is large in rodents (4-8-fold peak:trough), making time-of-day standardisation mandatory — all samples at the same ZT within ±30 min. Sex differences are substantial — female rodents show 2-2.5× greater corticosterone responses to acute restraint due to oestrogen-driven ACTH hyperresponsiveness. All HPA axis studies should be sex-stratified or specify the rationale for single-sex design. ACTH must be sampled from plasma (EDTA + protease inhibitor + immediate centrifugation at 4°C) within 15 min of collection due to ACTH degradation kinetics.
The DST (dexamethasone suppression test) provides the most informative single readout of HPA negative feedback status: administer DEX at ZT0, measure corticosterone at ZT8-10 the following day. Non-suppressors (post-DEX CORT >50nmol/L in rats) indicate GR resistance. This endpoint is sensitive to peptide-mediated GR restoration that may not be detected by basal corticosterone AUC alone.
Research Tool Summary: Adrenal and Cortisol Biology
Selank: GABAergic CRH neurone inhibition, corticosterone AUC −34%, DST GR restoration, hippocampal GR +34-38% — 0.3mg/kg i.n. CUS 21d, flumazenil 68% reversal control, DST + ACTH pulse amplitude readouts, diurnal corticosterone 08:00/20:00 sampling.
Semax: MC4R-CREB PVN CRH suppression, GR expression restoration, POMC transcriptional recovery — 50µg/kg i.n., SHU9119 and K252a controls, CUS or DEX-withdrawal model, ACTH + CRH mRNA + GR NR3C1 mRNA + DST endpoints.
DSIP: circadian HPA amplitude modulation, peak:trough ratio restoration — 5µg/kg i.p. ZT12 14d, peak:trough corticosterone ratio + ACTH pulsatility frequency ZT18-22 vs ZT6-10 endpoints, SCN VIP neuronal firing readout.
BPC-157: vagal-cholinergic CAP-NTS-PVN CRH suppression — 30µg/kg i.g. restraint model, bilateral vagotomy + MLA α7nAChR controls, gut FITC-4kDa + CRH mRNA + corticosterone endpoints.
GHK-Cu: hippocampal CA3 GR neuroprotection, Nrf2-mediated oxidative defence — 1mg/kg s.c. CUS 21d, ML385 control, hippocampal GR NR3C1 + TUNEL + DST + MDA endpoints.
MOTS-C: DEX-induced metabolic side-effect reversal, AMPK restoration — 5mg/kg i.p., compound C control, AMPK pThr172 + glucose + HOMA-IR + atrogene qPCR in GC side-effect model.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Selank, Semax, DSIP, BPC-157, GHK-Cu and MOTS-C for research and laboratory use. View UK stock →
